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Objective: The aim of the study was to estimate the 
cost-effectiveness of alternative therapeutic strategies 
for the management of chronic hepatitis B (CHB) in
Poland.
Methods: The model for the Polish health-care context
was based on clinical data from the literature and local
data on health-care resource utilization and unit costs.
Costs and effects of a population of CHB patients were
modeled using four scenarios, which attempt to reﬂect
real-life practice in which patients may receive any of the
treatment options available and in which a proportion of
patients may still receive no treatment because therapy is
not suitable. Strategies A and B assumed the availability
of both treatment options: the ﬁrst choice of treatment is
in A, lamivudine, and in B, interferon alpha (IFN-a). In
strategy C, the only approved treatment is IFN-a, and in
strategy D, the patients receive no antiviral treatment.
The outcome measures were HBeAg seroconversion 
and nonprogression to cirrhosis—the surrogate marker
with predictive value for improved survival. Only direct
medical costs were analyzed. The payer’s perspective and
time horizon of 1 year were adopted. One-way sensitiv-
ity analysis and extreme scenario analysis were 
performed.
Results: The best results in terms of seroconversion and
nonprogression to cirrhosis were achieved for strategy 
A, costs were lowest for strategy D, and strategies B 
and C were dominated by strategy A. The incremental
cost/effectiveness ratio (ICER) comparing strategy A with
strategy D was 57,855 Polish new zloty (PLN) per extra
seroconversion and 79,550 PLN per cirrhosis case
avoided.
Conclusions: Cirrhosis reduces estimated life expectancy
by 37.76 years and by 20 years among 30- and 50-year-
olds, respectively. The ICER for strategies A and D was
2105 PLN and 3978 PLN per life-years gained for the
population at ages 30 and 50, respectively, and was below
the suggested threshold for cost-effectiveness, based on
treatment costs for 1 year of hemodialysis in Poland
(62,400 PLN). Changing the value of key drivers for sen-
sitivity analysis did not have a signiﬁcant effect on the
ICER.
Keywords: lamivudine, interferon alpha, chronic hepati-
tis B, cost-effectiveness analysis.
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ABSTRACT
Introduction
Hepatitis B is an infectious disease caused by hepati-
tis B virus (HBV). It has been estimated that HBV
infection affects 2 billion people worldwide. HBV
infection has many clinical forms: from subclinical
carrier state to acute or chronic hepatitis, which
may lead to cirrhosis of the liver, hepatocellular 
carcinoma, hepatic failure, and death [1]. It is also
associated with extrahepatic diseases, such as mem-
branous glomerulonephritis, periarteritis nodosa,
and other vascular connective tissue diseases. The
WHO estimates that chronic hepatitis B is respon-
sible for approximately 1 million deaths each year
[2].
The number of chronic carriers is approximately
350 million [2]. Chronic hepatitis B is the most
common cause of hepatic cirrhosis and leads to
approximately 60% of all hepatocellular carcino-
mas [2,3]. It has been estimated that cirrhosis of the
liver and liver cancer accounts for the premature
death of 25% to 40% of chronic carriers [3]. There-
fore, chronic hepatitis B represents a signiﬁcant
health and economic burden. From the public
health policy perspective, the most important issue
is prevention of hepatitis B. However, the efﬁcacy
of the hepatitis B vaccine developed in early 1980s
is less than 100% and is ineffective in subjects with
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pre-existing HBV infection. This underscores the
importance of drugs used to treat chronic hepatitis
B. Interferon alpha (IFN-a) is the standard treat-
ment for chronic HBV. Lamivudine is currently
being introduced into clinical practice as an alter-
native for IFN-a. The aim of this study is to use 
a decision analysis model to estimate the cost-
effectiveness of alternative therapeutic strategies for
the management of chronic hepatitis B (CHB) in
Poland.
Epidemiology
From 1986 to 1990, the registered annual incidence
of hepatitis B in Poland was 14,000 to 15,000 [4,5],
and the prevalence of the disease was 37 to 40 per
100,000. Introduction of mandatory vaccination
against hepatitis B in 1994 resulted in a signiﬁcant
reduction in incidence from 4000 to 5000 in 1997
to 3800 in 1999 [4,5]. In 1997 and 1998, the preva-
lence was 15 to 18 per 100,000 and then declined
below 10 per 100,000 in 1999. According to data
from the National Institute of Hygiene, the preva-
lence of HBV carriers in Poland population is 1%
to 1.5% [4]. Thus, the number of subjects infected
with HBV in Poland is between 380,000 and
500,000.
The Need for Causal Treatment for Hepatitis B 
in Poland
Elimination of HBeAg can occur spontaneously in
up to 20% of infected patients [6] and in most
studies occurs in 9% to 14% of untreated patients
[7–12]. Assuming that 13% of carriers may spon-
taneously eliminate HBV and chronic hepatitis will
develop in as many as 20%, then 80,000 to 85,000
patients, including 35% to 40% of children
(28,000–32,000) required antiviral therapy in the
past 10 years in Poland. IFN-a has been available
in Poland since 1993. From 1993 to 1999, about
1500 adults and 2500 children infected with HBV
have undergone the therapy within the conﬁnes of
the program ﬁnanced by the Ministry of Health,
which accounts for only 5% of those requiring
treatment. Given that the drugs may be purchased
by individual patients and nongovernmental insti-
tutions such as research programs, which provide
treatment to an additional 500 to 700 patients, 
the number of HBV-infected patients receiving the
therapy in Poland is approximately 5000. So far,
continuous response to IFN-a therapy (disappear-
ance of HBsAg and loss of HBV DNA) does not
exceed 39% [13] or about 2000 patients. Thus, at
least 3000 patients previously treated with IFN-a
require retreatment. Once added to the number of
untreated patients requiring therapy, the number 
of Polish patients eligible for antiviral treatment is
78,000 to 83,000. This number is projected to
increase by at least 8000 patients per year for the
next 10 years.
Therapy for Chronic Hepatitis B
CHB infection is a result of nonelimination of HBV
and includes those cases in which HBV persists for
more than 6 months after infection. Therapy should
be provided to patients with CHB and symptomatic
liver disease including risk of progression of liver
disease (evidence for viral replication), extrahepatic
disease symptoms (glomerulonephritis, vasculitis),
relapse of the disease, advanced disease (decom-
pensated hepatic cirrhosis), and development of
infection in the patients after liver transplantation.
The aim of therapy is inhibition of HBV replica-
tion as indicated by HBeAg seroconversion (disap-
pearance of HBeAg and appearance of HBeAb) 
and improvement of liver function as indicated by
normalization of serum alanine aminotransferase
(ALT) levels and slowing or stopping of hepatic 
cirrhosis.
Two drugs have been licensed worldwide for
treatment of CHB: IFN-a and lamivudine. The
mechanism of action of the two drugs is different
as is patient selection for treatment. Both drugs
have been investigated extensively in monotherapy
and as combination therapy. In Poland, IFN-a is
part of standard drug therapy for CHB [13]. The
recommended dose is 5 to 10 million IU subcuta-
neously three times weekly for 3 to 6 months [1,14].
Lamivudine is a synthetic nucleoside analog exhibit-
ing anti-HIV and anti-HBV activity. The standard
dose of lamivudine is 100 mg orally once a day for
1 years [15]. In contrast to IFN-a, lamivudine turns
out to be a useful drug in HBV-infected patients
before liver transplantation [16]. It is a highly effec-
tive agent in patients with precore-mutant strains of
HBV [17] and exhibits beneﬁcial activity in patients
with decompensated hepatic cirrhosis [18].
HBeAg seroconversion after IFN-a treatment. Clin-
ical trials indicate that IFN-a induces elimination of
HBeAg in 20% to 40% of individuals with chronic
hepatitis B [19–26]. A meta-analysis of results from
15 randomized clinical trials in a total of 837 white
patients has revealed that IFN-a administered for 3
to 6 months and follow-up for 6 to 12 months stim-
ulate loss of HBV replication in about 20% more
patients receiving IFN-a compared to control [27].
A lower response rate (15–21%) has been found
among Asian patients who often become infected
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during childhood and in patients infected with HBV
precore mutants, which do not produce HBeAg
[28–32]. The less stringent end point, loss of HBeAg
rather than HBeAg seroconversion, is likely to
increase seroconversion rates in both treated and
untreated patients. An analysis of patients from 
10 randomized controlled trials, in which IFN-a
was administered to HBsAg- and HBeAg-positive
patients, revealed that in the IFN-a group, the
HBeAb appearance factor was 1.64, while HBeAg
disappearance factor was 1.8 [33]. Response to
IFN-a therapy depends on baseline patient charac-
teristics. Although the relative response is similar
for all patients, those with elevated pretreatment
transaminases and low baseline HBV DNA levels
get the greatest absolute beneﬁt from IFN-a therapy
[21,27,33].
HBeAg seroconversion after lamivudine treatment.
Treatment with lamivudine 100 mg p.o. daily for
1 year results in HBeAg seroconversion in 16% to
21% [15,34–36] and is signiﬁcantly higher for
lamivudine than for placebo [15,36]. The disap-
pearance rate of HBeAg after 1 year is higher than
seroconversion rate: 17% to 33% in the lamivu-
dine-treated group and 7% to 13% in the placebo
group [15,34–36]. In each phase III clinical trial,
loss of HBV DNA was observed in a majority of
patients who seroconverted from HBeAg to HBeAb.
This suggests that lamivudine-induced seroconver-
sion is associated with suppression of HBV replica-
tion [15,34–36]. As for IFN-a, elevated baseline
ALT is the strongest predictor of lamivudine-
induced HBeAg seroconversion. Multivariate analy-
sis showed that both ALT and the histologic activity
index (HAI) were signiﬁcantly correlated with
HBeAg seroconversion, although the contribution
of HBV DNA to the predicted response was negli-
gible [37]. Lamivudine increases the response rate
by a factor of less than 2 when ALT is less than two
times the upper limit of normal (ULN), but rises to
4 when ALT is less than ﬁve times the ULN [35,38].
Lamivudine versus IFN-a. In comparative clinical
trials of lamivudine versus IFN-a monotherapy, the
difference in seroconversion rates after daily oral
lamivudine 100 mg for 1 year versus 10 million IU
IFN-a subcutaneous three times a week after 4
months was not statistically signiﬁcant [35,39]. The
rate of HBeAg disappearance (22%) was identical
in both groups [39]. Indirect comparison between
lamivudine and IFN-a monotherapy compared to
placebo conﬁrms that there is no signiﬁcant differ-
ence in efﬁcacy of these drugs [27,36]. In compar-
ative trials of lamivudine versus IFN-a monother-
apy in patients with baseline ALT ≥ 2 ¥ ULN,
HBeAg seroconversion rates were 26.5 and 23.8,
respectively, which is not signiﬁcantly different [39].
Duration of response. IFN-a-induced HBeAg 
seroconversion is sustained in around 90% of pa-
tients [20,21,26,29,40,41]. Analysis of randomized,
placebo-controlled trials has indicated that HBeAg
seroconversion induced by lamivudine is durable 
in most patients. It persists for 6 months after 
cessation of therapy in 91% of patients and for
15 months in 83% of patients [34,42]. Persistence
of seroconversion at 21 months has been found in
86% of patients previously treated with lamivudine
[43], although the surrogate marker, loss of HBeAg,
was used in this study to assess seroconversion.
Worse results for lamivudine therapy have been
associated with a shorter (up to 12 months) treat-
ment period [44].
Based on current data one may conclude that
persistence of HBeAg seroconversion after lamivu-
dine or IFN-a monotherapy is equally durable, and
HBeAg seroconversion or disappearance of HBeAg
is a suitable time to discontinue lamivudine therapy,
as long-lasting therapeutic effects are ensured.
Improvement of Liver Histology
Histologic improvement is deﬁned as a reduction of
at least 2 points and worsening as an increase of at
least 2 points in the necroinﬂammatory score. One
year of lamivudine therapy signiﬁcantly reduced the
HAI score and prevented progression to ﬁbrosis in
HBeAg (+) patients [15,35,36,45–47]. Lamivudine
shows histologic beneﬁt in about 50% of patients,
whereas IFN-a does in 45% [36]. The difference
between these treatments is clearer when disease
progression is taken as the outcome measure: wors-
ening of histology was noted in 7% to 11% patients
treated with lamivudine, whereas IFN-a and
placebo were associated with worsening of histol-
ogy in about 30% patients [15,35]. Pooled results
of data from three clinical studies [15,39,45]
provide evidence that treatment with lamivudine
reduces the rate of progression to cirrhosis, deﬁned
as a score of 4 on the ﬁbrosis component of the
Knodell histologic activity index [46]. The fre-
quency of progression to cirrhosis after 1 year was
1.8% (4 of 219 patients), 7.1% (7 of 99 patients),
and 9.5% (4 of 42 patients) in those treated with
lamivudine 100 mg/day, placebo, and IFN-a,
respectively [46].
The difference between lamivudine and IFN-a
can be explained in part by the fact that these are
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overall results, including responders and nonre-
sponders. Patients who received lamivudine mono-
therapy derived histologic beneﬁt irrespective of
their HBeAg seroconversion status, whereas the his-
tologic response after IFN-a treatment is usually
observed only in patients who have demonstrated a
serologic response [15,35,48]. Fattovich et al. [49]
suggests that in patients with CHB and evidence of
active viral replication, the 5-year incidence of cir-
rhosis is 15% to 20%. On the basis of these data,
Wong et al. [50] estimated that the annual proba-
bility of developing cirrhosis was 1% for patients
who had HBsAg and 12.1% for patients who had
HBeAg. The other important factor hampering the
comparison of histologic results for lamivudine
with other therapies in several studies is that all
biopsies were taken at the end of lamivudine
therapy but 6 months after withdrawal of IFN-a
therapy.
Efﬁcacy of Lamivudine in Patients with YMDD-
Variant HBV
In some patients, lamivudine therapy may lead to
emergence of an HBV mutant, YMDD-variant
HBV, which is less susceptible to lamivudine activ-
ity. After 1 year of lamivudine treatment, YMDD-
variant HBV was detected in 14% to 32% of
patients [15,35,36], and after 2 and 3 years of
therapy, in 42% and 52% of Asian patients, res-
pectively [51,52]. Within 3 to 4 months of stop-
ping therapy, occurrence of YMDD-variant HBV
decreased from 32% to 29% [36], from 31% to
21% [35], and from 27% to 21% [34]. Among
patients receiving lamivudine, emergence of
YMDD-variant HBV decreases, but HBeAg sero-
conversion is not precluded [15]. After 3 years of
therapy with lamivudine, seroconversion had
occurred in 22% of patients with, and in 50% of
patients without, YMDD-variant HBV [51].
Tolerability of IFN-a and Lamivudine
Adverse effects associated with IFN-a therapy
include depression, psychoses, suicidal tendencies,
severe ﬂu-like symptoms, neutropenia, and tran-
sient exacerbation of disease symptoms. These 
contribute to poor compliance and the need for
monitoring during therapy [19]. As many as 20%
of patients require dosage reductions and 5% to
10% discontinue IFN-a therapy [53] because of
adverse events. Parenteral administration of IFN-a
is inconvenient. Lamivudine exhibits a better toler-
ability than IFN-a, which has a safety proﬁle similar
to that observed for placebo [15,45,54,55]. Fur-
thermore, the drug may be given to those patients
for whom IFN-a is contraindicated such as in
patients with advanced liver disease, receiving
immunosuppressive therapy (especially after organ
transplantation), or with a history of psychiatric or
autoimmune disorders. Because of the oral route of
administration, lamivudine may also be used in
patients who refuse parenteral therapy.
Materials and Methods
Target Population
The patient population used in the model was rep-
resentative of those likely to receive antiviral treat-
ment in Poland. All of the patients were positive 
for HBeAg (patients with the precore-mutant virus
were excluded), had moderately elevated ALT and
had chronic hepatitis B initially, had not yet pro-
gressed to cirrhosis, and were IFN-a-naive. It was
assumed that patients were between the ages of 30
and 50, and 60% of the population was female.
Methods
The model for the Polish health-care context was
based on data from published clinical trials, expert
opinion, and local data on health-care resource uti-
lization and unit costs. The model was created with
Data 3.5 (Version 3.5.5, 1988–2000, TreeAge Soft-
ware, Inc., Williamstown, MA, USA). The costs 
and effects for a population of CHB patients were
modeled using four strategies based on real-life
practice in which patients may receive any of the
treatment options available, and a proportion of
patients may still receive no treatment because
therapy is not suitable. Strategies A and B assumed
the availability of both treatment options. In strat-
egy A, all patients eligible for lamivudine are treated
with lamivudine. Patients ineligible for lamivudine
receive IFN-a or no antiviral treatment if IFN-a
therapy is contraindicated due to adverse events.
Similarly, for strategy, B, all patients are treated
with IFN-a if eligible, and those ineligible for IFN-
a receive lamivudine or no antiviral treatment if
lamivudine therapy is not suitable. Patients in
whom adverse events cause cessation of IFN-a
receive no further antiviral therapy. In strategy C,
the only approved treatment available is IFN-a,
which is given only to those patients eligible for
IFN-a. Patients ineligible for IFN-a and patients in
whom IFN-a treatment was discontinued because
of adverse events receive no antiviral therapy. In
strategy D, patients receive no antiviral treatment.
Strategy D provides the baseline from which the
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incremental costs and outcomes of the introduction
of lamivudine can be assessed.
The outcome measures of the model were:
• HBeAg seroconversion, deﬁned as the loss of
HBeAg and the appearance of HBeAb;
• Nonprogression to cirrhosis, the surrogate
marker for improved survival [56].
The model, as represented in Figure 1, allows 
for calculation of the cost per patient, the HBeAg
seroconversion rate, the proportion of patients not
progressing to compensated cirrhosis, and the incre-
mental cost/effectiveness ratios (ICER). The ICER
for cost per cirrhosis case avoided was converted
into cost per life-year gained using life tables and
estimates (of) the effect of hepatic cirrhosis on mor-
tality.
The perspective of health-care payers and a time
horizon of 1 year were adopted.
Probabilities of Events in the Model
Initially, all patients are HBeAg (+). After 1 year,
they may be in one of three states of health: sero-
conversion, chronic hepatitis B without cirrhosis, 
or compensated hepatic cirrhosis. The proportion
of patients eligible for lamivudine therapy (80%;
range, 60–90%) and IFN-a (60%; range, 40–70%)
were obtained from an expert panel of Polish hepa-
tologists (n = 55), whose clinics manage 90% of
patients in Poland treated for CHB. Data were col-
lected using a questionnaire and discussed during 
a consensus meeting [57]. Based on information
obtained from literature [53], it is assumed that dis-
continuation of IFN-a is required in 10% of
patients because of intolerance and occurs halfway
through the treatment period. Probabilities of sero-
conversion after lamivudine administration (0.18)
and IFN-a (0.19) were based on results of a ran-
domized, controlled, head-to head, comparative
trial of lamivudine versus IFN-a for 52 weeks [35].
The estimated probability of spontaneous serocon-
version after 52 weeks without therapy (0.06) took
into account the comparative study of lamivudine
versus placebo in white patients, in which the
response rate to lamivudine was similar to results
obtained in the key trial for lamivudine versus 
IFN-a [36]. The probability of progression to cir-
rhosis was based on data from three clinical trials
evaluating liver histologic response after admin-
istration of lamivudine, IFN-a, and placebo
[15,39,45]. Analysis of pooled data from these 
trials showed that the frequency of progression to
cirrhosis at 52 weeks was 1.8, 7.1, and 9.5% in
those treated with lamivudine, placebo, and IFN-a,
respectively [46]. In the three studies analyzed, all
patients who seroconverted, regardless of whether
they received lamivudine, IFN-a, or placebo, did
not progress to cirrhosis [15,39,45]. Assuming that
progression to cirrhosis occurs only in patients who
did not seroconvert, the probability of progression
is 0.02 for lamivudine, 0.12 for IFN-a, and 0.08 for
untreated patients. The differences observed can be
explained in part by the fact that those who received
lamivudine monotherapy derived histologic beneﬁt
irrespective of their HBeAg seroconversion status,
whereas the histologic response after IFN-a treat-
ment is usually observed only among patients
having demonstrated a serologic response
[15,35,48]. The difference between IFN-a and
placebo demonstrated by pooled analysis of data
from three studies does not appear valid, as it is dif-
ﬁcult to assess the relative efﬁcacy of the alterna-
tives without a direct comparison of pooled and
individual trial results. Because the probability of
progression to cirrhosis among patients treated 
with IFN-a who failed to seroconvert is 0.12 [46],
similar to the annual probability of developing cir-
rhosis in HBeAg-positive patients estimated by
Wong et al. [50], the rate of progression to cirrho-
sis used in the model is 0.12 both for IFN-a and for
no therapy. All baseline probabilities for the model,
along with the range of values used in the sensitiv-
ity analysis, are given in Table 1.
Costs
Analysis from the health-care payers’ perspective
assessed only direct medical costs resulting from the
diagnosis of CHB, qualiﬁcation for treatment, and
treatment. Information on current treatment prac-
tices (dosage, frequency of consultations, hospital-
ization, and procedures) was obtained from the
expert panel of Polish hepatologists (n = 55). Data
were collected using a questionnaire and discussed
during a consensus meeting [57]. It was assumed
that IFN-a dosing was 5 mIU, three times weekly
for 6 months, as per Polish clinical practice recom-
mendations. In head-to-head comparison of lamivu-
dine and IFN-a for 52 weeks, IFN-a was dosed at
10mIU three times weekly for 4 months versus
lamivudine 100mg tablet once daily for 52 weeks.
Qualifying for therapy with IFN-a or lamivudine
requires consultation with a specialist and review of
laboratory parameters (HBsAg, HBeAg, HBeAb,
DNA polymerase, blood cell count, erythrocyte sed-
imentation rate, protein fraction pattern platelets,
aminotransferases, and bilirubin and for IFN-a-
treated patients only, creatinine, blood urea nitro-
gen, and proteinuria), abdominal ultrasound, and
410 Orlewska
progress to cirrhosis
P_cirser
no progression
#
seroconversion
p_serLAM
progress to cirrhosis
p_cirLAM
no progression
#
no seroconversion
#
treated with LAM
p_trLAM
eligible for LAM
p_LAM
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_serIFN
progress to cirrhosis
p_cirIFN
no progression
#
no seroconversion
#
treated with IFN
p_trIFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
IFN intolerance
#
eligible for IFN
p_IFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
no treatment
p_nt
ineligible for IFN
#
ineligible for LAM
#
scenario A
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_serIFN
progress to cirrhoss
p_cirIFN
no progression
#
no seroconversion
#
treated with IFN
p_trIFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
IFN intolerance
#
eligible for IFN
p_IFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_serLAM
progress to cirrhosis
p_cirLAM
no progression
#
no seroconversion
#
eligible for LAM
p_LAM
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
no treatment
p_nt
ineligible for LAM
#
ineligible for IFN
#
scenario B
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_serIFN
progress to cirrhoss
p_cirIFN
no progression
#
no seroconversion
#
treated with IFN
p_trIFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
IFN intolerance
#
eligible for IFN
p_IFN
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
no treatment
p_nt
ineligible for IFN
#
scenario C
progress to cirrhosis
p_cirser
no progression
#
seroconversion
p_sernt
progress to cirrhosis
p_cirnt
no progression
#
no seroconversion
#
no treatment
p_nt
scenario D
patient with chronic hepatitis B
trategy
trategy
trategy
trategy
Figure1 Decision tree for 1-year model.
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liver biopsy. Patients treated with IFN-a are moni-
tored more intensively. Patients are hospitalized ini-
tially for 10 days and reviewed a total of 11 times
by the specialist, at which time liver function tests,
total blood counts, and HBeAg and HBsAg mea-
surements are performed. Two thyroid function
tests are performed during the 52-week period. Fur-
thermore, 72 ambulatory visits are required during
the treatment period to allow for parenteral admin-
istration. Patients treated with lamivudine undergo
specialist consultations, liver function tests, full
blood counts, and measurement of HBeAg and
HBsAg monthly for the ﬁrst 6 months and every
3 months thereafter. It was conservatively assumed
that patients who did not receive any antiviral drug
did not receive any medication to treat symptoms
of disease and had the same schedule of consulta-
tions and tests as patients receiving lamivudine and
that those patients who progressed to cirrhosis did
so at midyear. Estimated costs of developing com-
pensated cirrhosis were based on expert opinions.
During the ﬁrst 6 months of treatment for these
patients, liver biopsy, activated partial thrombo-
plastin time, proteinogram, alpha-fetoprotein, and
treatment with essential phospholipids and lactu-
lose are recommended. Specialist consultations and
other tests are included in the intensive monitoring
associated with antiviral treatment.
Price data for the cost of drugs were obtained
from the pharmaceutical wholesale price list 2002
[58] and from the Medical Services Schedule 2002
[59] for the costs of specialist consultations, tests,
investigations, and hospitalizations, as summarized
in Table 2. All costs were assessed in Polish new
zloty (PLN) (1 US$ = 4 PLN). Discounting was 
not required because of the 1-year analytical
horizon. Cost data applied to the model are listed
in Table 3.
Sensitivity Analysis
One-way sensitivity analyses were used to test the
robustness of the study results to changes in clini-
cal and economic parameters by varying:
1. Probabilities of HBeAg seroconversion after
lamivudine, IFN-a, and no treatment (upper and
lower values from phase III studies in Asian and
white patients);
2. The percentage of patients eligible for either
lamivudine or IFN-a (upper and lower values
from information on questionnaires collected by
Polish hepatologists);
3. The percentage of patients discontinuing IFN-a
therapy (upper and lower values from published
studies);
4. The percentage of progression to cirrhosis in
patients treated with either lamivudine or IFN-
a or untreated (upper and lower values from
clinical studies);
5. The acquisition cost for high-dose IFN-a treat-
ment as per clinical trials;
6. The cost of routine medical management 
of patients treated with lamivudine or with 
IFN-a both with and without the cost of 
hospitalization.
The extreme scenario analysis made use of best
estimates of key parameters for IFN-a and worst
estimates of these for lamivudine. This scenario is
plausible because the probabilities represent upper
and lower values derived from questionnaires and
from clinical studies.
Table 1 Probability of events in the model: values used in the baseline analysis and in sensitivity analyses
Probabilities used in
Variable Baseline probability Reference sensitivity analyses
Eligible for lamivudine therapy 0.8 Expert opinion 0.6–0.9*
Eligible for IFN-a therapy 0.6 Expert opinion 0.4– 0.7*
IFN-a intolerance 0.1 53 0.0–0.2†
HBeAg seroconversion
Treated with lamivudine 0.18 35 0.16–0.21‡
Treated with IFN-a 0.19 35 0.19–0.21‡
Untreated 0.06 36 0.04–0.07‡
Progression to cirrhosis
Patients who seroconverted 0.0
Patients who did not seroconvert
Treated with lamivudine 0.02 46 0.018–0.12†
Treated with IFN-a 0.12 46, 50 0.09–0.12†
Untreated 0.12 50 0.07–0.12†
*Upper and lower values from questionnaire collected information from Polish hepatologists.
†Upper and lower values from published literature.
‡Upper and lower values from clinical trials in Asian and white patients, with end point of HBeAg seroconversion.
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Table 2 Prices of drugs and some diagnostic and therapeutic procedures used in patients with chronic hepatitis B
Resources item Price (PLN) Data source
Drugs
Lamivudine (acquisition cost of 28 tablets, 0.1 g each) 437.80
IFN-a (acquisition cost of 1 amp., 5mIU) 170.68
Essentiale forte (acquisition cost of 50 capsules) 33.12 Pharmaceutical wholesale price list, 2002
Lactulose (acquisition cost of 150ml) 8.34
Laboratory tests (per test)
Serologic examination
HBsAg 12.0
HBeAg 36.0
HBeAb 36.0
DNA polymerase 200.0
Blood cell count + platelets + blood smear + ESR 24.0
Proteinogram 17.0
APTT 5.0 Medical Services Schedule, 2002
Aminotransferases 12.0
Bilirubin 5.0
Proteinuria 3.0
BUN 6.0
Creatinine 6.0
Thyroid hormones 34.0
Abdominal ultrasonography 35.0 Medical Services Schedule, 2002
Liver biopsy 120.0 Medical Services Schedule, 2002
Ambulatory visits 8.0 Medical Services Schedule, 2002
Specialist consultations 18.0 Medical Services Schedule, 2002
Hospitalization 2500.0 Medical Services Schedule, 2002
Abbreviations:APTT, activated partial thromboplastin time; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate.
Table 3 Cost data for the model
(A) Costs associated with antiviral treatment
Cost per patient for 1 year (PLN)
Resource item IFN-a Lamivudine No treatment
Drug 12,289 5691 —
Specialist consultations 216 (12 ¥ 18 PLN) 144 (8 ¥ 18 PLN) 144 (8 ¥ 18 PLN)
Ambulatory visits (parenteral 576 (72 ¥ 8) — —
administration of drug)
Tests
HBsAg, HBeAg, HBeAb 1,008 (12 ¥ 84 PLN) 672 (8 ¥ 84 PLN) 672 (8 ¥ 84 PLN)
DNA polymerase 200 (1 ¥ 200 PLN) 200 (1 ¥ 200 PLN) 200 (1 ¥ 200 PLN)
Blood cell count 288 (12 ¥ 24 PLN) 192 (8 ¥ 24 PLN) 192 (8 ¥ 24 PLN)
Proteinogram 17 (1 ¥ 17 PLN) 17 (1 ¥ 17 PLN) 17 (1 ¥ 17 PLN)
Aminotransferases 144 (12 ¥ 12 PLN) 96 (8 ¥ 12 PLN) 96 (8 ¥ 12 PLN)
Bilirubin 60 (12 ¥ 5 PLN) 40 (8 ¥ 5 PLN) 40 (8 ¥ 5 PLN)
BUN, creatinine, proteinuria 15 (1 ¥ 15 PLN)
Thyroid hormones 68 (2 ¥ 34 PLN)
Abdominal ultrasonography 35 (1 ¥ 35 PLN) 35 (1 ¥ 35 PLN) 35 (1 ¥ 35 PLN)
Liver biopsy 120 (1 ¥ 120 PLN) 120 (1 ¥ 120 PLN) 120 (1 ¥ 120 PLN)
Hospitalization 2,500 (1 ¥ 2500 PLN) — —
Total 17,536 7207 1516
(B) Additional costs associated with progression to cirrhosis
Resource item Cost per patient for 6 months (PLN)
Liver biopsy 120 (1 ¥ 120 PLN)
Test
APTT 5 (1 ¥ 5 PLN)
Proteinogram 17 (1 ¥ 17 PLN)
Alpha-fetoprotein 26 (1 ¥ 26 PLN)
Drugs 238
Total 407
Note:Values in parentheses indicate the number of counting units and unit price of resources used.
Abbreviations:APTT, activated partial thromboplastin time; BUN, blood urea nitrogen.
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Results
Base-Case Analysis
Based on the decision tree in Figure 1 it is expected
that introduction of lamivudine will result in a
much higher proportion of CHB patients being
treated than the actual situation in which IFN-a is
the only approved drug treatment (92% in strategy
A and B vs. 60% in strategy C). It is expected that
80% of CHB patients would be treated with
lamivudine if lamivudine were the drug of choice
(strategy A) and that 32% of patients would receive
lamivudine if IFN-a were the drug of choice (strat-
egy B). The proportion of patients completing treat-
ment with IFN-a (and accounting for IFN-a
intolerance was 10.8% in strategy A and 54% in
both strategies B and C.
Introduction of lamivudine results in a higher
number of patients who seroconvert and a conse-
quent delay in disease progression. HBeAg sero-
conversion rates for strategies A, B, C, and D were
0.17, 0.169, 0.13, and 0.06, respectively, as sum-
marized in Table 4. The higher HBeAg seroconver-
sion rates for patients in strategies A and B were
due to the higher proportion of patients who
received active treatment, as efﬁcacies for both
lamivudine and IFN-a in terms of seroconversion
rates were assumed to be comparable (0.18 vs.
0.19). Table 5 indicates the proportion of patients
who did not progress to cirrhosis with strategies A,
B, C, and D, and were 0.97, 0.93, 0.9, and 0.89,
respectively.
As indicated in Tables 4 and 5, the total costs per
patient treated according to strategies B and C 
were higher than total costs for strategy A. This is
directly attributable to the drug acquisition cost and
to costs of consultations and monitoring during
treatment, which are much higher for IFN-a than
for lamivudine as summarized in Table 3.
Because of higher costs and lower effectiveness,
strategies B and C are dominated by strategy A.
Tables 4 and 5 show the outcome of comparison 
of strategy A with strategy D: an incremental cost
of 57,855 PLN per extra seroconversion and of
79,550 PLN per cirrhosis avoided.
Conversion of Proxy Outcomes to 
Life-Years Gained
Nonprogression to cirrhosis is the surrogate marker
with predictive value for improved survival [60].
Because the outcome of interest in a cost-effective-
ness analysis is life-years gained (LYG), information
on cirrhosis cases avoided should be translated into
life expectancy. To calculate life-years gained under
a health program that prevents progression to cir-
rhosis, the life expectancy of persons with and
without hepatic cirrhosis is estimated, starting with
the age of the patient at the initiation of the
program. This method requires information 
Table 4 Summary of the results of the model*
Effectiveness (HBeAg Incremental Cost Incremental ICER (PLN per extra
Strategy seroconversion rate) effectiveness (PLN) cost (PLN) HBeAg seroconversion)
D 0.06 1,562
C 0.13 0.07 10,644 9082 129,743
B 0.169 0.039 12,453 1809 46,385
A 0.17 0.001 7,926 -4527 -4,527,000
Strategies B and C are dominated by strategy A
D 0.06 1,562
A 0.17 0.11 7,926 6364 57,855
*The alternative strategies are ranked according to their effectiveness (HBeAg seroconversion rate).
Table 5 Summary of the results of the model*
Effectiveness  Incremental Cost Incremental ICER (PLN per cirrhosis
Strategy (nonprogression to cirrhosis) effectiveness (PLN) cost (PLN) case avoided)
D 0.89 1,562
C 0.90 0.01 10,644 9082 908,200
B 0.93 0.03 12,453 1809 60,300
A 0.97 0.04 7,926 -4527 -113,175
Strategies B and C are dominated by strategy A
D 0.89 1,562
A 0.97 0.08 7,926 6364 79,550
*The alternative strategies are ranked according to their effectiveness (nonprogression to cirrhosis).
414 Orlewska
published in life tables and estimates of the effect of
hepatic cirrhosis on mortality.
According to data from literature, patients with
CHB and hepatic cirrhosis have a 5-year survival
rate of 55% [56] or 45% mortality over 5 years.
Assuming a constant annual probability of dying
from hepatic cirrhosis after disease occurrence, the
following calculations are performed.
The estimated annual probability of dying from
hepatic cirrhosis (h), is given by the equation
Life expectancy of a k-year-old person (Ek) was
estimated using this equation and assumes that
almost all patients die by age 100 years:
(1)
where z(n) is the portion of the initial population
that survives to year n.
For a person without hepatic cirrhosis, z(n) is
expressed with the formula
(2)
where d(i) is annual probability of dying at age i.
Similarly, but taking into account excess mortal-
ity from the disease, z(n) for a person with hepatic
cirrhosis occurring at age k is expressed as
(3)
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where h is the annual probability of dying from
hepatic cirrhosis and d(i) is the annual probability
of dying from other causes at age i.
Expected life-years lost, if hepatic cirrhosis
occurs at age k, is calculated as the difference in
expected life-years.
(5)
Results of these calculations are listed in Table 6.
Assuming that 60% of the population is female,
hepatic cirrhosis reduces estimated life expectancy
by 37.76 years, if occurring in 30-year-old individ-
uals, and by 20 years in 50-year-olds.
Determining Cost-Effectiveness (Cost per 
Life-Years Gained)
Table 5 compares strategy A with strategy D and
gives the incremental cost of 79,550 PLN per cir-
rhosis case avoided. Because hepatic cirrhosis
reduces estimated life expectancy in the population
under study by 37.76 years if it occurs in a 30-year-
old person, and by 20 years in a 50-year-old person,
the incremental cost-effectiveness ratio comparing
strategies A and D is 2105 PLN per LYG for a pop-
ulation at age 30 and 3978 PLN per LYG for a 
population at age 50. Comparing this result with
the suggested threshold for cost-effectiveness, cal-
culated on the basis of 1 year of hemodialysis treat-
ment at a cost of 62,400 PLN, it can be concluded
that strategy A offers substantial beneﬁt at reason-
able cost to the Polish health-care system.
Sensitivity Analyses
To test the robustness of the model, parameters in
two categories, probability and cost, were varied
and are indicated in Tables 7 and 8. In all cases,
parameters that were not varied remained at the
Loss in life expectancy
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Table 6 Life expectancy for k-year-old men and women and the effect of hepatic cirrhosis in k-year-old men and women on
life expectancy (k = 30 and k = 50)
Life expectancy without Life expectancy after progression Loss of life expectancy because
Population hepatic cirrhosis (years) to hepatic cirrhosis (years) of hepatic cirrhosis (years)
30-year-olds
Women 49.02 8.26 40.76
Men 41.32 8.10 33.26
50-year-olds
Women 30.11 7.8 22.31
Men 23.90 7.26 16.64
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base-case values. The sensitivity of the model was
based on the change in the dominance report and
the incremental cost-effectiveness ratios when com-
paring strategies A and D. In most cases, changing
the value of key drivers for sensitivity analysis
across the range described above did not have any
signiﬁcant effect on the dominance report nor on
the incremental cost-effectiveness ratios. The least
favorable ICER when comparing these strategies is
when the probability of progression to cirrhosis in
lamivudine-treated patients who failed seroconver-
sion is 0.12, as indicated in Table 8. This is due to
a marked reduction in the incremental effectiveness
ratio in terms of nonprogression to cirrhosis for
strategies A and D, in which case the incremental
cost per cirrhosis case avoided increases to 483,964
PLN. Therefore, the cost per life-year gained is
3302 PLN for a 30-year-old person and 6225 PLN
for a 50-year-old person and remains within the
range of cost-effectiveness.
When the probability of HBeAg seroconversion
is altered from the base value to 0.21 for IFN-a
or to 0.16 for lamivudine, the best effectiveness, in
terms of HBeAg seroconversion rate, is achieved
Table 7 Sensitivity analysis (outcome measure: HBeAg seroconversion rate)
ICER (PLN per
Selected extra HBeAg
Variable Baseline value Dominance report seroconversion)
Primary analysis B, C dominated by A A vs. D: 57,855
Sensitivity analyses, one-way
Patients eligible for
IFN-a 0.6 0.7 B, C dominated by A A vs. D: 59,391
0.4 B, C dominated by A A vs. D: 54,573
Lamivudine 0.8 0.6 B, C dominated by A A vs. D: 70,705
0.9 B, C dominated by A A vs. D: 52,233
Seroconversion rates
IFN-a 0.19 0.21 C dominated by A A vs. D: 56,719
B vs.A: 628,706
Lamivudine 0.18 0.21 B, C dominated by A A vs. D: 47,477
0.16 C dominated by A A vs. D: 67,674
B vs.A: 554,783
No treatment 0.06 0.04 B, C dominated by A A vs. D: 54,573
Progression to cirrhosis in 0.2 0.12 B, C dominated by A A vs. D: 58,076
patients treated with
lamivudine who do
not seroconvert
Cost of IFN-a 12,289 PLN 16,385 PLN* B, C dominated by A A vs. D: 62,077
Cost of procedures
IFN-a 5,247 PLN 2,747 PLN† B, C dominated by A A vs. D: 55,130
Lamivudine 1,516 4,016 PLN‡ B, C dominated by A A vs. D: 75,986
Extreme scenario analysis§
Eligible for
IFN-a 0.6 0.7 C dominated by a blend A vs. D: 77,404
of A and B with a
coefﬁcient of inequity
between 0.236 and 0.857
LAM 0.8 0.6 B vs.A: 206,531
Seroconversion rates 0.19 0.21
(IFN-a) (IFN-a)
0.18 0.16
(LAM) (LAM)
Progression to cirrhosis 0.12 0.12
(IFN-a) (IFN-a)
0.02 0.12
(LAM) (IFN-a)
IFN-a intolerance 0.1 0.0
Additional clinically plausible scenarios
Seroconversion rates 0.19 0.21 C dominated by A A vs. D: 63,324
(IFN-a) (IFN-a)
0.18 0.16 B vs.A: 269,441
(LAM) (LAM)
*10 mIU three times weekly for 4 months.
†Cost of hospitalization excluded.
‡Cost of hospitalization included.
§Probabilities represent upper and lower values from questionnaire-collected information and from clinical studies.
Abbreviation: LAM, lamivudine.
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Table 8 Sensitivity analysis (outcome measure: nonprogression to cirrhosis)
ICER (PLN per
Selected cirrhosis case
Variable Baseline value Dominance report avoided)
Primary analysis B, C dominated by A A vs. D: 79,550
Sensitivity analyses, one-way
Patients eligible for
IFN-a 0.6 0.7 B, C dominated by A A vs. D: 84,352
0.4 B, C dominated by A A vs. D: 73,486
Lamivudine 0.8 0.6 B, C dominated by A A vs. D: 115,605
0.9 B, C dominated by A A vs. D: 68,581
Seroconversion rates
IFN-a 0.19 0.21 B, C dominated by A A vs. D: 80,490
Lamivudine 0.18 0.21 B, C dominated by A A vs. D: 80,265
0.16 B, C dominated by A A vs. D: 81,087
No treatment 0.06 0.04 B, C dominated by A A vs. D: 78,579
Progression to cirrhosis in 0.2 0.12 B, C dominated by A A vs. D: 483,964
patients treated with
lamivudine who do not
seroconvert
Cost of IFN-a 12,289 PLN 16,385 PLN* B, C dominated by A A vs. D: 86,682
Cost of procedures
IFN-a 5,247 PLN 2,747 PLN† B, C dominated by A A vs. D: 76,982
Lamivudine 1,516 4,016 PLN‡ B, C dominated by A A vs. D: 106,105
Extreme scenario analysis§
Eligible for
IFN-a 0.6 0.7 C dominated by a blend A vs. D: 645,034
of A and B with a
coefﬁcient of inequity 
between 0.236 and 0.857
LAM 0.8 0.6 B vs.A:
1,721,093
Seroconversion rates 0.19 0.21
(IFN-a) (IFN-a)
Progression to cirrhosis 0.18 0.16
(LAM) (LAM)
IFN-a intolerance 0.12 0.12
(IFN-a) (IFN-a)
0.02 0.12
(LAM) (IFN-a)
0.1 0.0
Additional clinically plausible scenarios
Seroconversion rates 0.19 0.21 B, C dominated by A A vs. D: 80,819
(IFN-a) (IFN-a)
0.18 0.16
(LAM) (LAM)
*10 mIU three times weekly for 4 months.
†Cost of hospitalization excluded.
‡Cost of hospitalization included.
§Probabilities represent upper and lower values from questionnaire-collected information and from clinical studies.
Abbreviation: LAM, lamivudine.
with strategy B. The incremental cost per HBeAg
seroconversion when comparing strategy B to strat-
egy A is 628,706 PLN when the probability of sero-
conversion after IFN-a is 0.21, 554,783 PLN when
the probability of seroconversion after lamivudine
is 0.16, and 269,441 PLN when the probability of
seroconversion is adjusted for both drugs (0.21 for
IFN-a; 0.16 for lamivudine). These incremental
cost-effectiveness ratios are less favorable than
when scenario A is compared to scenario D, as indi-
cated in Table 7.
The aim of extreme scenario analysis is to
examine the sensitivity of the results under the most
optimistic and clinically plausible assumption about
the effect of IFN-a treatment and the most pes-
simistic assumption about the effect of lamivudine
treatment. The probabilities represent upper and
lower values from information collected on ques-
tionnaires and from clinical studies. It was assumed
that 70% of patients were eligible for IFN-a
therapy; that all were treated; that 60% of patients
were eligible for lamivudine therapy; that the prob-
ability of HBeAg seroconversion was 0.21 and 0.16
after IFN-a and lamivudine treatment, respectively;
and that the probability of progression to cirrhosis
after IFN-a and lamivudine was 0.12. In this case,
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the best effectiveness in terms of HBeAg serocon-
version and nonprogression to cirrhosis was
achieved with strategy B. Strategy C was dominated
by a combination of strategies A and B. The incre-
mental cost-effectiveness ratios for strategies B and
A, as indicated in Tables 7 and 8, were 206,531
PLN per additional seroconversion and 1,721,093
PLN per cirrhosis case avoided. Thus, cost per life-
year gained is 45,580 PLN for a 30-year-old person
and 86,055 PLN for a 50-year-old. Comparing 
this result with the suggested threshold for cost-
effectiveness, calculated on the basis of 1 year of
hemodialysis treatment at a cost of 62,400 PLN, it
can be concluded that, for a 50-year-old population,
strategy B is not a cost-effective alternative to strat-
egy A. When comparing strategies A and D, the
incremental costs per additional seroconversion and
per cirrhosis case avoided are 77,404 PLN and
645,034 PLN, respectively. As in the base-case
analysis, strategy A remains the cost-effective alter-
native to no treatment. The results of the sensitiv-
ity analyses indicate that, in terms of the magnitude
of the ICER and of dominance, the model is robust
over the very wide range of parameter values men-
tioned above.
Budgetary Impact Analysis
Based on Polish epidemiologic data it was deter-
mined that, within the next 10 years, at least 8000
patients with CHB annually should receive treat-
ment. Extrapolation of model results for this pop-
ulation led to the tentative conclusion that use of
strategy A rather than strategy B or strategy C could
save between 36,216,000 PLN and 21,747,200
PLN per year. Additional beneﬁt is associated with
the greater effectiveness of strategy A. Of the 8000
individuals following strategy A, B, or C, the
numbers of patients seroconverting would be 1360,
1352, and 1040, respectively, and the numbers of
patients not progressing to cirrhosis would be 7760,
7440, and 7200, respectively. Because of the greater
number of patients who seroconverted and who 
did not progress to cirrhosis following strategy A, 
compared to strategies B and C, a reduction of 
potential expenditures associated with antiviral
retreatment and progression of the disease is
implied.
Discussion
The increased pressure on health-care budgets in
most countries has emphasized the need to demon-
strate the value for money of new health technolo-
gies. New drugs and new drug indications must be
assessed for cost-effectiveness over and above safety
and efﬁcacy. Because this information is considered
an important part of the decision-making process,
speciﬁcally reimbursement, the key requirement 
for any cost-effectiveness report is that assumptions
used in models reﬂect real-life practice.
Chronic hepatitis B usually follows a slow
course, and it is difﬁcult to carry out long-term,
prospective, clinical–economic studies to estimate
costs and effects associated with administration of
different antiviral agents. In such cases, the decision
model developed is based on data obtained from
reliable, controlled, randomized clinical trials; the
natural history of the disease; expert panels; infor-
mation collected on questionnaires; current treat-
ment practices; patient characteristics; etc.
Previous models for the treatment of CHB
[50,61,62] used hypothetical cohorts of patients
treated or not with IFN-a. Only in one model was
an attempt made to reﬂect real-life practice—one
hypothetical cohort of patients received lamivudine,
IFN-a, or no treatment (scenario A); another
received either IFN-a or no treatment (scenario B);
while the third cohort received no treatment (sce-
nario C) [63]. The authors based their model on
patients, treatment practices, and costs in Australia.
In the model presented here, hypothetical cohorts
of patients received one of the available antiviral
drugs or no treatment (strategies A and B), IFN-a
or no treatment (strategy C), or no treatment (strat-
egy D), attempting thereby to reﬂect real-life prac-
tice in Poland. As in the Australian study, the
proportions of patients eligible for lamivudine and
IFN-a therapy were obtained from expert panels
and supported by data from the questionnaire 
distributed to hepatologists. There are some pop-
ulation differences—patients in Australia are pre-
dominantly migrants from southeast Asia and have
been shown to be more resistant to IFN-a—and dif-
ferences in treatment practices. The different con-
clusions from the Australian and the Polish studies
may be due to the use of two strategies, A and B,
in the Polish study. Strategies A and B and scenario
A in the Australian study assumed the availability
of lamivudine, but differed in terms of ﬁrst-line
therapy, thereby allowing one to determine which
should be the drug of choice. Strategies C and D
were relevant to scenarios B and C in the Australian
study. The availability of lamivudine as per strate-
gies A and B (Polish) and scenario A (Australian)
increases the proportion of patients receiving antivi-
ral therapy and the rates of seroconversion and of
nonprogression to cirrhosis. In the Australian study,
this beneﬁt was achieved for a small overall increase
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in health-care costs. The incremental cost-
effectiveness ratio for lamivudine (scenario A) was
A$3341 per additional seroconversion and A$5272
per cirrhosis avoided, compared to the scenario in
which IFN-a is the only available treatment [63]. A
similar situation occurred when strategy B (IFN-a
as the drug of choice) was compared to strategy C
(only IFN-a is available) in the Polish study: the
incremental cost-effectiveness ratio was 46,385
PLN per additional seroconversion and 60,300
PLN per avoided cirrhosis. In the case where strat-
egy A (lamivudine as ﬁrst-line treatment) was the
alternative to strategy C, better outcome and cost
savings were possible. Because of higher costs and
lower effectiveness, strategies B and C were domi-
nated by strategy A. Compared to no treatment,
lamivudine was the cost-effective drug of choice
when benchmarked against other currently funded
health-care programs in Poland.
The results of this pharmacoeconomic analysis
should be interpreted within the limitations of the
model and data on which they are based. The time
horizon was restricted to 1 year. Because of lack of
real long-term cost data for management of subse-
quent stages of CHB, it was impossible to apply a
long-term Markov model. Conversion of the ICER
for cost per cirrhosis case avoided into cost per LYG
based on 1-year treatment costs alone was possible.
Efﬁcacy of IFN-a and lamivudine was based on
results of current randomized, controlled, interna-
tional, clinical trials limited to 1-year follow-up. 
If new data become available, the analysis may
require veriﬁcation. The proportion of patients
receiving IFN-a and lamivudine was based on infor-
mation from Polish experts in hepatology. Presum-
ably, these data reﬂect the current situation in
Poland, but it might be worthwhile conducting a
national survey to conﬁrm this.
In the model it was assumed that IFN-a dosage
was 5mIU, three times weekly for 6 months, based
on the recommendations of Polish National 
Specialists of Infectious Diseases and on clinical
practice in Poland. The approved dosage is 5 to 
10mIU, three times weekly for 4 to 6 months. In
comparative clinical trials of IFN-a versus lamivu-
dine, IFN-a was given at a dose of 10mIU, three
times weekly for 4 months. This dose was tested in
sensitivity analysis and did not have any signiﬁcant
effect on the ICER.
Because the rate of HBeAg seroconversion is a
key driver in the model, patients with HBeAg (–)
HBV (precore mutant) were not taken into account
in the analysis. In some countries, up to 30% of
patients have developed precore mutant HBV. In
this group, a lower response rate and higher rate of
recurrence have been observed after IFN-a therapy
[40,64], while the response rate (loss of HBV DNA
and normalization of ALT level) after lamivudine
was the same as that observed in patients infected
with the wild-type virus [17]. Including these
patients in the analysis would beneﬁt lamivudine
therapy, but an end point, other than HBeAg sero-
conversion, should be included.
The emergence of YMDD-mutant HBV is the
other clinically relevant aspect of lamivudine
therapy. The YMDD mutant corresponds to sus-
tained amino acid sequence in HBV DNA poly-
merase, the enzyme that is highly sensitive to
lamivudine. Its inhibition leads to arrest of viral
replication. Substitution of isoleucine (YIDD) or
valine (YVDD) for methionine may result in
decreased lamivudine activity after its emergence.
Clinical studies indicate that YMDD mutant may
occur in 14% to 32% of patients receiving lamivu-
dine therapy for 1 year [15,35,36]. YMDD mutant
does not replicate strongly compared to wild-type
HBV, and therefore, lamivudine therapy in patients
infected with YMDD mutant still causes reduction
of viral DNA, and in some patients HBeAg sero-
conversion may occur [65,66]. Clinically relevant
data regarding YMDD HBV are readily available,
and therefore, its inﬂuence on the results of lamivu-
dine therapy in this model was not considered. It
seems, however, that this does not change the con-
clusions, because even patients with YMDD mutant
have reduced viral replication after lamivudine
therapy compared to no treatment and also experi-
ence improvements in liver histology.
In the present model, the perspective of the
health-care payer was taken. Analysis from the soci-
etal perspective should also consider indirect costs,
but estimation of these in Poland is impossible
without adequate studies. Considering that the
availability of lamivudine increases the proportion
of treated patients with a consequent increase in the
rate of HBeAg seroconversion, lost productivity 
in the group receiving lamivudine should be lower
than in patients receiving only IFN-a therapy or no
treatment. This suggests that indirect costs alone
may increase the beneﬁts of lamivudine therapy
with the result that incorporation of indirect costs
into the model should provide additional evidence
for the cost effectiveness of lamivudine.
Conclusions
This model demonstrates the costs and beneﬁts rel-
evant to the introduction of lamivudine in clinical
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practice. Strategy A (lamivudine as ﬁrst-line treat-
ment) yields the best results in terms of HBeAg sero-
conversion rate and nonprogression to cirrhosis.
Strategy B (IFN-a as the drug of choice) and strat-
egy C (only IFN-a) are dominated by strategy A,
which ensures a greater effectiveness at lower cost.
Strategy A is cost-effective when compared to no
treatment when benchmarked against other cur-
rently funded health-care programs in Poland. The
one-way sensitivity analysis and extreme scenario
analysis revealed that changing the value of key
drivers and parameters did not have any signiﬁcant
effect on the results.
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